|Verified for the 2026 Plan Year & CMS Part D Guidelines
Quick Answer: Medicare **does not cover** Wegovy if it is prescribed strictly for cosmetic weight loss due to a statutory ban under the 2003 MMA Act. However, Medicare Part D plans **do cover Wegovy** if it is prescribed to reduce the risk of major cardiovascular events (like heart attack or stroke) in adults who are overweight or obese. Additionally, under the **Medicare GLP-1 Bridge demonstration program (running through Dec 31, 2027)**, eligible beneficiaries meeting specific clinical BMI and risk tiers can bypass standard restrictions to access Wegovy for a flat **$50 monthly copay**.
Prescription medications for weight management and related conditions often raise questions about insurance eligibility and reimbursement. When patients receive a treatment recommendation, one of the most common questions is whether Medicare covers Wegovy and, if so, under what circumstances.
Medicare coverage for medications depends on how the drug is classified and the medical condition it is prescribed to treat. Coverage rules can vary across Medicare programs, so eligibility may differ depending on plan structure and approved indications.
Understanding these coverage guidelines helps beneficiaries, especially those new to Medicare, determine whether a medication may qualify for reimbursement or require alternative payment options. Knowing how Medicare evaluates prescription drugs can also help patients discuss appropriate treatment and coverage options with their healthcare providers.
Why Medicare Doesn’t Cover Wegovy for Weight Loss
The coverage exclusion is not an accident. It traces to a federal law that still controls Part D coverage today, and knowing why the rule exists helps you work around it.
The 2003 Law That Still Blocks Weight-Loss Drug Coverage
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibited Part D plans from covering drugs prescribed for weight loss. Congress classified weight-loss medications as cosmetic rather than medically necessary, partly in the aftermath of the fen-phen scandal, when a popular diet pill was linked to serious heart disease.
While the 2003 law still technically prohibits standard Part D plans from covering weight-loss drugs, the July 1, 2026, Medicare GLP-1 Bridge creates a legal ‘carve-out.’ For the first time in history, Medicare is using its demonstration authority to bypass this ban, providing a direct pathway for obesity treatment that doesn’t rely on a heart disease diagnosis.
What Changed in 2024 – and Why It Matters
In March 2024, the FDA approved Wegovy for a second use: reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are also overweight or obese. That approval changed the legal landscape for Medicare.
Part D plans gained the authority to cover Wegovy for that cardiovascular indication. Think of it this way: the same medication, prescribed for two different purposes, is treated entirely differently under Medicare rules. The purpose your doctor documents on the prescription determines whether Medicare will pay.
When Does Medicare Cover Wegovy – and Who Qualifies?
Now that a coverage pathway exists, the question becomes whether you qualify. The answer depends on your specific diagnosis and the plan you carry.
Medicare Part D Coverage – The Cardiovascular Exception
To qualify for the $50 Wegovy copay under the Medicare GLP-1 Bridge (July 1, 2026 – Dec 31, 2027), you must meet one of these three finalized clinical tiers:
-
Category A (Severe Obesity): A BMI of 35 or higher. No additional health conditions are required for approval.
-
Category B (Obesity with Comorbidity): A BMI of 30 or higher WITH one of the following: heart failure (HFpEF), uncontrolled hypertension (systolic >140 or diastolic >90 while on two medications), or Stage 3+ Chronic Kidney Disease.
-
Category C (Overweight with High Risk): A BMI of 27 or higher WITH pre-diabetes, a history of heart attack/stroke, or symptomatic sleep apnea.
Expert Tip: If you have already lost weight on Wegovy and your BMI is now below these thresholds, your doctor can submit an “Initial-State Attestation.” This proves you met the criteria when you started therapy, protecting your $50 coverage from being revoked due to your success.
Even when you meet these criteria, coverage is not automatic. Most plans require prior authorization, meaning your doctor must submit documentation of your cardiovascular diagnosis before the plan approves the drug.
Here’s a quick scenario. You are a 68-year-old Medicare beneficiary with a history of heart attack and a BMI of 31. Your cardiologist recommends Wegovy to reduce your risk of a second event. Your Part D plan may cover Wegovy, provided it appears on your formulary, and prior authorization is submitted. Without that cardiovascular diagnosis on file, coverage would be denied.
Does this sound like your situation? It’s worth a direct conversation with your doctor about how the prescription is documented before it’s submitted to your plan.
- RELATED: Medicare Part B vs. Part D
Do Medicare Advantage Plans Cover Wegovy?
Medicare Advantage (Part C) plans set their own formularies, so coverage varies significantly across plans. Some Medicare Advantage plans that cover Wegovy do exist, but there is no universal rule.
To check whether your plan covers Wegovy:
- Visit medicare.gov/plan-compare and log in to your account
- Enter Wegovy as a medication you need covered
- Compare plans and their out-of-pocket costs for that drug
Plans adjust their formularies annually, so reviewing your options each open enrollment period, October 15 through December 7, is the most reliable way to stay covered.
If you need help reviewing your Medicare Advantage plan or comparing coverage options, Life143 can help you understand your benefits and evaluate which plans may cover medications like Wegovy.
How Much Does Wegovy Cost With Medicare?
When Part D covers Wegovy, it typically falls into the specialty tier, meaning you pay a percentage rather than a flat copay. Here is what that looks like:
- Without coverage, Wegovy’s list price runs approximately $1,349 per month
- With Part D specialty tier coverage, coinsurance of 25% to 33% equals roughly $325 to $430 per month until you reach your annual out-of-pocket cap
- 2025/2026 out-of-pocket cap – under the Inflation Reduction Act, the annual Part D cap is $2,000 to $2,100; once you reach it, covered drugs cost nothing for the rest of the year
Starting July 1, 2026, the cost landscape for Wegovy changes entirely. Under the Medicare GLP-1 Bridge, eligible beneficiaries will pay a flat $50 monthly copay for all formulations of Wegovy (including the new daily pill).
Crucial 2026 Update: This $50 copay operates outside your standard Part D benefit. This means it does not count toward your $2,100 out-of-pocket cap, but it also means you won’t be hit with ‘Specialty Tier’ coinsurance that previously cost seniors $400+ per month
And in 2027, Medicare’s negotiated price for semaglutide (the active ingredient in Wegovy) is set at $274 for a 30-day supply, a meaningful reduction from today’s list price.
What Are Your Options If Medicare Won’t Cover Wegovy?
Not qualifying for coverage today does not mean you are without options. Several programs can reduce your out-of-pocket costs while you wait for the 2026 and 2027 changes.
Consider these practical pathways:
- Novo Nordisk Patient Assistance Program – a savings card for eligible patients without insurance coverage; income requirements apply
- Medicare Extra Help (Low-Income Subsidy) – reduces Part D out-of-pocket costs for eligible beneficiaries; as Wegovy gains broader formulary coverage in 2027, Extra Help could significantly lower your share.
- HSA funds – money accumulated in a Health Savings Account before Medicare enrollment can be used tax-free for Wegovy even without plan coverage
- Covered GLP-1 alternatives – if you have Type 2 diabetes, Ozempic or Rybelsus may already be covered; ask your doctor whether a covered alternative fits your clinical need.s
- Open enrollment plan switch – use the October 15 through December 7 window to move to a plan whose formulary includes Wegovy for your qualifying condition
- Switch to Wegovy Oral: If you are needle-phobic, the 2026 Bridge Program includes the Wegovy daily pill at the same $50 price point, providing a more convenient alternative to the weekly injection.
What would it mean for your health goals if a plan covered Wegovy at $50 a month instead of $1,300? For many beneficiaries, answering that question makes the research effort worthwhile.
Your Coverage Answer Starts With One Step
Medicare’s rules around Wegovy can feel confusing because the same medication is treated differently depending on why it is prescribed. While coverage for weight loss remains restricted, new FDA approvals and upcoming policy changes are opening real opportunities for certain beneficiaries.
The key is understanding your diagnosis, your Part D formulary, and whether your plan requires prior authorization. Reviewing these details with a knowledgeable advisor can help you avoid unnecessary costs and identify coverage options you may not realize are available.
Want help reviewing your Medicare prescription coverage?
Contact Life143 to discuss your Medicare plan, prescription coverage options, and strategies for managing medication costs. We help you understand your benefits, compare plans, and make confident decisions about your healthcare coverage.
FAQ About the 2026 Wegovy Bridge
Does the $50 copay count toward my $2,100 Part D Out-of-Pocket Maximum?
No. Because the Medicare GLP-1 Bridge operates through a separate CMS central processor and not your insurance plan’s standard benefit, these payments are considered “off-benefit.” While you save nearly $1,300 a month on the drug, the $50 payments do not count toward your annual deductible or out-of-pocket cap
Is this $50 price permanent?
The current Bridge program is a temporary demonstration. However, in April 2026, CMS officially extended the program through December 31, 2027. This means you are guaranteed the $50 price point for at least 18 months. Beyond 2027, coverage will likely transition to the “BALANCE Model,” which Life143 is currently tracking for our clients.
Can I get the $50 copay if I already have heart disease?
If you have a heart condition, your doctor can choose to prescribe Wegovy through your standard Part D plan or the Bridge program. At Life143, we help you calculate which “lane” is cheaper: the Bridge offers a lower monthly cost ($50), but the Part D lane counts toward your $2,100 annual limit. For many high-cost patients, the “lane” you choose can save you an additional $2,000 a year.
What happens if I lose weight and my BMI drops below the 2026 requirements?
You will not lose your coverage. Your doctor can submit an “Initial-State Attestation” to CMS. This documents that you met the BMI requirements (e.g., BMI of 35+) when you started the medication, ensuring you can continue maintenance doses at the $50 rate even after you reach your goal weight.
